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Abstract
Biomaterial-based strategies to restore connectivity after lesion at the spinal cord are focused on
bridging the lesion and providing an favourable substrate and a path for axonal re-growth.
Following spinal cord injury (SCI) a hostile environment for neuronal cell growth is established by
the activation of multiple inhibitory mechanisms that hamper regeneration to occur. Implantable
scaffolds can provide mechanical support and physical guidance for axon re-growth and, at the
same time, contribute to alleviate the hostile environment by the in situ delivery of therapeutic
molecules and/or relevant cells. Basic research on SCI has been contributing with the description
of inhibitory mechanisms for regeneration as well as identifying drugs/molecules that can target
inhibition. This knowledge is the background for the development of combined strategies with
biomaterials. Additionally, scaffold design is significantly evolving. From the early simple hollow
conduits, scaffolds with complex architectures that can modulate cell fate are currently being
tested. A number of promising pre-clinical studies combining scaffolds, cells, drugs and/or nucleic
acids are reported in the open literature. Overall, it is considered that to address the multi-factorial
inhibitory environment of a SCI, a multifaceted therapeutic approach is imperative. The progress in
the identification of molecules that target inhibition after SCI and its combination with scaffolds
and/or cells are described and discussed in this review.
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Spinal cord injury
Spinal cord injury (SCI) can be caused by compression, contusion,
penetration or maceration of the spinal cord tissue, being very het-
erogeneous in cause, as well as in outcome. A lesion inflicted to the
spinal cord leads to the interruption of motor and sensory neuronal
pathways, resulting in the loss of motor, sensory and involuntary
functions below the point of injury. Depending on the severity and
location of trauma, SCI can be complete or incomplete, leading to
different degrees of functional impairment. The primary injury trig-
gers widespread cell death, including of neurons, oligodendrocytes,
astrocytes or precursor cells. In parallel, oedema, ischemia and hae-
morrhage take place, resulting in the enlargement of the damaged
area and creating, ultimately, a fluid-filled cyst. Subsequently, in the
sub-acute phase of SCI, a cascade of events that constitute the sec-
ondary damage begins with oligodendrocyte apoptosis and loss of
myelin, glutamate excitotoxicity, increase of free radicals and in-
flammation. This secondary injury results in a protracted period of
tissue destruction. In the chronic phase, a glial scar is formed.
Overall, the lesion site constitutes a particularly hostile scenery for
axonal regeneration (see [1–4] for a review).
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For a long time it was considered that neurons from the central
nervous system (CNS) could not regenerate and the field of research
on regeneration on the follow up of a SCI was quiescent. About
three decades ago the first indications that regeneration can occur in
the CNS were obtained using peripheral nerve grafts in the CNS [5,
6]. More recently, it was demonstrated that, although for short dis-
tances, axonal sprouting occurs after lesion, contributing to com-
pensatory recovery and to the formation of new pathways that
bypass the lesion [7]. Despite this regenerative potential, the fact is
that after SCI the interrupted neuronal connections are not rewired
and the impaired functions cannot be completely restored. This fail-
ure is mainly attributed to the establishment of an inhibitory envi-
ronment for regeneration, namely by activation of inhibitory
pathways, formation of a cavity (that withdraws the physical sup-
port for re-growth) and by the formation of a scar tissue that consti-
tutes a real physical hurdle for regeneration [8–10]. Nevertheless,
the last thirty years of research contributed with important findings,
both at the molecular and cellular level, on the mechanisms underly-
ing re-growth inhibition after SCI. Although these still did not suc-
ceed in being translated into the clinical setting, they formed solid
ground for the current view on regenerative therapies to be applied
in the aftermath of SCI, and the field agrees that to address such a
multi-faceted inhibitory environment a combinatorial therapeutic
strategy will be required [4].
In the aftermath of SCI—the methylprednisolone
debate
The current interventions in SCI are limited to spinal stabilization,
rehabilitation and complication-prevention [11]. For some time, the
recommended pharmacological treatment for SCI was the systemic
administration of high doses of methylprednisolone (MP). MP is a
synthetic glucocorticoid with anti-inflammatory and antioxidant
properties, thought to induce neuroprotection and reduce the sec-
ondary damage upon injury [12]. A clinical trial in 1990 indicated
the bolus injection of MP (30 mg/kg) during the first 8 h after injury
as a mean to improve neurological recovery [13]. Based on this re-
port, MP has been prescribed worldwide for non-penetrating acute
SCI. However, the use of MP has been debated as well as the design
of that clinical trial, and the performed data analysis was considered
of dubious value [14, 15]. Other studies have reported limited bene-
ficial effect of MP and secondary effects caused by the high dose ad-
ministrated, like gastric bleeding [14, 16]. Additionally, a
randomized clinical trial for head injury demonstrated that the mor-
tality rate increases 2% with administration of MP [17]. Still, the
controversy remains as there is recent experimental data supporting
the use of MP for SCI [18–20] but also negative reports are being
published [21, 22]. Consequently, the use of MP is no longer ‘stan-
dard of care’ for acute SCI, although it is still in medical practice.
Inhibitory signals and therapeutic approaches
Lesion to the spinal cord leads to the activation of a number of
events that turn the lesion site into a very hostile substrate for axo-
nal re-growth. Three processes have been identified as main contrib-
utors to the inhibitory environment: the activation of an
inflammatory response, the accumulation of myelin debris and the
formation of the glial scar. Based on the multiple sources of inhibi-
tory signalling, diverse strategies have been proposed to address it.
Overall, these strategies focus on (i) promoting neuroprotection of
uninjured neurons, (ii) suppressing inhibitory signalling, (iii) replace
damaged/death cells, (iv) induce neuroplasticity and/or (v) bridge
the disrupted neuronal connections (see Fig. 1).
Inflammation and immunomodulation
When a lesion occurs, mechanical forces contribute to the initial dis-
ruption of the blood brain barrier (BBB). The increase of the BBB
permeability is taken as a prelude to the inflammatory response eli-
cited by CNS trauma [23]. This triggers activation of endothelial
and glial cells, promoting the release of vasoactive molecules—
reactive oxygen species, kinins, nitric oxide and histamines—that
influence endothelial function and enhance the BBB permeability,
contributing to the enlargement of the injured area, exacerbation of
damage and neurotoxicity. Moreover, inflammatory cells are re-
cruited, namely: microglia (resident macrophages of the CNS),
monocytes, neutrophils and lymphocytes. This process occurs within
days after injury. Nonetheless, high levels of pro-inflammatory cyto-
kines, such as interleukin (IL)-2 and IL-6, are detected in patients
with chronic SCI, pointing to the existence of a continuous and
prolonged inflammatory process [24].
Traditionally, inflammatory cell infiltration in the CNS is regarded
as pathological [25]. However, the role of inflammation and inflam-
matory cells after SCI has been issue of active debate.
Neuroinflammation is considered a dual-edged sword and both neu-
rotoxic and neuroprotective properties are ascribed to inflammatory
cells [16]. Macrophages were proposed to be the secondary damage
effectors in SCI and their depletion showed to enhance axonal sprout-
ing and improve motor function in a contusion SCI model [26]. On
the other hand, injection of macrophages was explored as mean to im-
prove recovery after SCI. M. Schwartz’s group defends that a well-
controlled innate and adaptive immune response is pivotal for repair
in SCI [27, 28], basing their claim on the observation that the injection
of ‘alternatively ex vivo activated macrophages’ in a spinal cord lesion
promotes functional recovery [29]. Macrophages activated prior injec-
tion in the spinal cord by co-culturing with peripheral nerves showed
increased phagocytic and proteolytic activity, and reduced pro-inflam-
matory bias. In the late nineties, this work was very controversial.
Nowadays, macrophage polarization is well accepted (see [30–32] for
review) and to learn how to control the opposing functions that these
cells can exert depending on their phenotype is a topic of interest in
many different research fields, including in SCI [28, 32, 33]. In fact,
the modulation of macrophage function is the rationale behind the
use of some neuroprotective drugs, such as MP, minocycline [34] or
other anti-inflammatory molecules, like IL-10 [35, 36]. MP is the only
drug that achieved the clinical setting for SCI treatment as described
previously in this review. Minocycline is an antibiotic with anti-
inflammatory properties. The drug is known due to its immunomodu-
latory properties, being able to tune the expression of cytokines,
attenuate oligodendrocyte and microglia cell death, and improve func-
tional recovery in rat SCI models [37, 38]. In the phase I/II clinical
trial for acute SCI, minocycline showed to be safe and, although the
functional evaluation did not accomplish statistical significance, there
is a clear tendency towards improvement that encouraged the phase
III clinical trial [39], currently recruiting participants [40].
Taming myelin inhibition
Damage to the spinal cord results in neural cell death. In particular
oligodendrocyte cell death leads to axon demyelinization and can re-
sult in neuron degeneration. Additionally, the loss of contact be-
tween oligodendrocytes and axons, due to neuron cell death, can
also induce oligodendrocyte degeneration or even death.
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It is well known that oligodendrocytes and myelin are inhibitory
substrates for axonal growth [41, 42] and myelin debris accumula-
tion at the injury site is one of the critical events halting regenera-
tion. Several molecules present in myelin were already identified as
inhibitors for axonal growth including Nogo-A, myelin-associated
glycoprotein, oligodendrocyte-myelin glycoprotein and its down-
stream effectors such as Nogo-66 receptor [43], Ras homolog gene
family member A (RhoA) and Rho-associated protein kinase
(ROCK) [44, 45].
The inefficient clearance of myelin debris by microglia and mac-
rophages in the CNS (in opposition to the effective cleaning medi-
ated by macrophages in the peripheral nervous system where
regeneration occurs [46]) is considered, by several authors, as the
main responsible for CNS residual ability to regenerate [1]. In view
of that, the injection of autologous macrophages at the injury site
has been investigated in a clinical trial (ProCord, Proneuron
Biotechnologies). Improvements were detected in 5 out of the 16
acute phase patients [25], but when tested in phase II, the treatment
showed no improvement on the primary outcome comparing to
non-treated individuals [47].
Alternatively, blocking myelin-mediated inhibition was explored
with the use of antibodies against Nogo-A. Three different antibod-
ies have been tested in pre-clinical models over the last 15 years [48–
50]. A Phase I clinical trial using an humanized anti-Nogo antibody,
ATI355 produced by Novartis, showed the safety of the treatment,
but results related to the efficacy were not disclosed [51]. The anti-
Nogo therapy is applied in acute phase patients, since the time win-
dow for application of this therapy is limited, showing a progressive
loss of responsiveness [52].
Inactivation of RhoA, a downstream effector of myelin-
associated pathways, has been shown by several groups to overcome
axonal growth inhibition by individual inhibitors and by myelin in
general. Inactivation of RhoA by the application at the site of injury
of the toxin C3 (Clostridium botulinum) promotes an extensive re-
generation and functional recovery in mice [53]. Hindlimb recovery
was also reported after administration of the toxin or Y27632—a
specific inhibitor for ROCK [44]. RhoA is a convergence molecule
for many inhibitors of axonal regeneration and it is, for that reason,
a promising target for SCI therapeutics [25]. The first results of a
phase I clinical trial using a cell-permeable Rho antagonist, called
BA-210 (Cethrin, a recombinant protein), were published by Alseres
Pharmaceuticals. Cethrin was administered by extradural applica-
tion with a fibrin sealant to patients with acute cervical SCI during
spinal decompression surgery conducted within 72 h after injury
[54]. Twelve months after intervention, 5 out of 13 patients (38%)
showed marked recovery of motor and sensory function after treat-
ment, as measured by a 2-grade improvement or higher in the
American Spinal Cord Injury Association (ASIA) impairment scale
[55]. A phase IIb trial was planned, sponsored by Bioaxone
Biosciences, but by the end of 2014 it was withdraw, because the
drug was licensed to Vertex Pharmaceuticals.
Ibuprofen is used worldwide as a non-steroidal anti-inflamma-
tory drug. Its action has been attributed to the inhibitory effect on
cyclooxygenase and it is used to reduce pain, fever and acute inflam-
matory reaction [56, 57]. In 2007, it was described for the first time
that ibuprofen can inhibit the activation of RhoA in a SCI scenario
[58]. The drug prevents myelin inhibition of neurite outgrowth by
reducing RhoA activation in vitro, and when administrated in vivo
after SCI improves functional recovery [58, 59] and corticospinal
axonal regeneration [58]. Even though a recent re-assessment study
reports only partial replication of the results obtained in 2007 [60],
the number of publications that demonstrate positive effects of ibu-
profen on nerve regeneration is significant [61, 62] and the use of
this drug is considered very promising [63]. Indeed, a clinical trial to
assess safety of the administration of the drug in SCI patients was
launched recently and is recruiting patients [40].
Overcoming the glial scar
As a lesion to the spinal cord progresses into a chronic phase, a glial
scar is formed. The glial scar is mainly an astrocytic tissue consisting
of hyperfilamentous astrocytes, with processes tightly packed, many
Figure 1. Spinal cord injury (SCI) therapeutic approaches currently under investigation.
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gap and tight junctions and limited extracellular space [64]. The
scar is formed to isolate the injury, reseal the BBB and prevent the
damage of the spared tissue and the spreading of excitotoxicity and
cytotoxic molecules [65]. However, the glial scar represents a me-
chanical barrier for axonal re-growth, being also a source of chemi-
cal inhibitors for regeneration. Chondroitin sulphate proteoglycans
(CSPGs) produced by astrocytes are present in the extracellular ma-
trix in the CNS and, in pathological conditions, are the major con-
stituent of the glial scar, being an inhibitory signal for axonal
growth [66]. In this context, CSPGs have been targeted in SCI thera-
peutics and it was demonstrated that digestion of CSPGs by chon-
droitinase ABC promotes axon regeneration and plasticity, leading
to functional recovery of locomotor and proprioceptive behaviour
after SCI [67]. Treatment with this enzyme is likely to be advanta-
geous even 7 days after injury [68], making this strategy particularly
interesting for non-acute spinal cord lesions. However, the origin of
the enzyme (bacteria), as well as the degradation products formed,
have been issue of concern due to the possibility of triggering a spe-
cific immune response, hindering clinical translation [69].
Moreover, these degradation products can exert some inhibitory in-
fluence on the growth of spinal axons [70]. The use of lentivirus-
based delivery of a modified chondroitinase gene (that encodes for a
secreted form of the enzyme that can be expressed by mammalian
cells) is under investigation, as a mean to circumvent some of these
caveats [71, 72].
Protecting injured neurons and repopulating the injury
Neurotrophins are molecules with interest in the context of SCI due
to their important role in neural development, survival and regener-
ation [73]. Injection of nerve growth factor (NGF) [74], brain-
derived growth factor (BDNF) or neurotrophin-3 (NT-3) [75] was
performed in SCI animal models with different degrees of success.
Bradbury et al. [75] found that NT-3 is significantly more effective
than BDNF promoting the growth of injured axons in a rat dorsal
crush model. A large-scale animal study indicated that the local ap-
plication of BDNF can induce neuroprotection if applied at high
doses and shortly after trauma [76]. Other neurotrophic factors
such as glial-derived growth factor (GDNF) [75] and insulin-like
growth factor (IGF-1) [76] were already proposed to treat SCI.
Regardless the promising results obtained in vitro and in animal
models, a clinical trial using systemic delivery of growth factors for
diabetic neuropathy showed limited efficacy and significant side ef-
fects [77], slowing down the progress of new clinical studies with
these molecules. Currently, the use of neurotrophic factors appears
to be particularly relevant when combined with drug/gene delivery
strategies and/or cell-based therapies [4].
Other molecules have been investigated for treatment of SCI
based on their neuroprotective effects, being riluzole the most suc-
cessful example. Riluzole is a sodium channel blocker and the ratio-
nale for its use in acute SCI is that removing sodium excess upon
injury, neuronal depolarization is prevented, reducing the accumula-
tion of glutamate and excitotoxicity. It has been shown that the ad-
ministration of riluzole after SCI in rats reduces oedema and
improves motor recovery [78]. A clinical trial enrolling 36 patients
was carried out, aiming at evaluating the safety of the drug adminis-
tration within 12 h after injury. Full results await publication, but a
phase II/III trial is currently recruiting [40].
According to clinicaltrials.gov [40], 10% of the open clinical
trials for SCI use cellular therapies. The implantation of cells (in-
cluding stem cells of different origin) in SCI holds the promise of
repopulating the injury site, promoting the production of growth
factors and cell plasticity. Current literature suggests that cell-based
therapies will be of particular interest in acute or sub-acute phases
of SCI, since transplantation in chronic patients showed to yield lim-
ited functional benefit [79]. The use of cells for SCI treatment was
reviewed in detail elsewhere [79–83].
Biomaterial-based strategies for SCI—
Engineering an implantable bridge
Designing a bridge to re-connect the injured spinal cord encloses sev-
eral challenges, namely facing the hostile environment at the lesion
site or providing adequate mechanical support. Nonetheless, to de-
velop an implantable device provides a unique opportunity to com-
bine different therapeutic signals in a single platform (Fig. 2). Nerve
regeneration research based on the use of biomaterials was primarily
focused on the development of scaffolds that connect the lesion site,
filling the cavity formed upon lesion, providing physical support and
a path for axonal re-growth and limiting cellular infiltration from
the periphery. These scaffolds have been evolving from the simple
hollow conduit to more sophisticated devices with improved physi-
cal guidance architectures combined with cells, drugs or nucleic
acids material. Overall, scaffolds are expected to allow the modifica-
tion of the inhibitory environment at the lesion site and, conse-
quently, contribute to the process of regeneration [84]. This review
focused in particular on the evolution of nerve conduits and porous
scaffolds in terms of design and as versatile platforms for the devel-
opment of combinatorial therapeutic strategies.
Candidate biomaterials
The use of nerve conduits to bridge a nerve lesion was firstly ex-
plored for peripheral nervous system regeneration, as an alternative
to autologous nerve grafting (see [85, 86] for a review). Upon the ev-
idence that neurons from the CNS can regenerate into peripheral
nerve grafts [5], the development of nerve conduits was extrapolated
to the treatment of SCIs. Ideal requisites of such nerve conduits in-
clude permeability to oxygen and nutrients, limited swelling, flexi-
bility without kinking [85], versatility in terms of architectures and
dimensions, should allow sterilization as well as to be easy to handle
and suture [46].
Several materials have been used to prepare bridges for SCI, in
particular biodegradable materials, either natural or synthetic, as re-
viewed in Table 1. The use of synthetic materials to prepare nerve
conduits has the advantage of the control over manufacturing pa-
rameters and the possibility to fine-tune the chemical structure, me-
chanical properties and degradation rate (when applicable). Among
them, aliphatic polyesters, like poly(lactide) (PLA), poly(glycolide)
(PGA) and their copolymers, have been the most explored [87–89],
probably encouraged by the fact that these are approved by the
Food and Drug Administration (FDA) (see Table 1). Another popu-
lar synthetic polymer in the nerve conduit research field is poly(e-
caprolactone) (PCL) [90, 91], despite the limited number of in vivo
studies concerning its application in a SCI scenario. PCL has a
slower degradation rate in comparison to PGA or PLA, and to tune
its properties, it has been co-polymerized with 1,3-trimethylene car-
bonate [92, 93] or ethyl ethylene phosphate [94]. Porous scaffolds of
poly(trimethylene carbonate-co-e-caprolactone) [P(TMC-CL)]
showed to support peripheral nerve regeneration in vivo [95]. In the
CNS context, P(TMC-CL) showed to stimulate neuronal polariza-
tion and axonal elongation, favouring neurite outgrowth even when
in an inhibitory environment [96].
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Natural polymers can be generally considered as biocompatible
and non-toxic. These properties have made natural polymers attrac-
tive materials for the preparation of nerve tissue engineering con-
structs [97]. Chitosan [98, 99] and collagen [100] are popular
natural materials used to prepare nerve conduits (for the peripheral
or CNS). Other materials applied as scaffolds for SCI include hyal-
uronic acid, agarose or gelatin, (see Table 1). To combine the advan-
tages of both natural and synthetic polymers, blending have been
actively investigated, as shown by the different combinations of PCL
with gelatin [101], collagen [102] or chitosan [103].
To enhance the bioactivity of conduits, these have been modified
with cell adhesion peptides [104, 105] or extracellular matrix pro-
teins like fibronectin [88, 99, 106, 107], or laminin [88, 89, 98,
108]. The incorporation of extracellular components on nerve
bridges holds the premise of improving cell adhesion and promoting
axon path finding.
Some of the above mentioned materials could be processed as
solid conduits as well as injectable materials. The use of injectable
materials is considered of particular interest in SCI lesions where the
dura matter is not compromised. In this case, the use of in situ cross-
linking hydrogels that can fill the cavity formed without causing
further damage to the tissue is preferable to the implantation of a
solid device [84]. Detailed revision on hydrogel-based strategies for
SCI is out of the scope of this review and can be found elsewhere
[82, 138].
An important class of materials that has also been investigated
for the preparation of nerve conduits is the one of conductive poly-
mers. It has been shown that electrical stimulation increases neurite
outgrowth [139]; therefore, to provide scaffolds with conductive
properties can positively contribute for the regeneration process.
However, synthetic conductive polymers, like poly(pyrrole) and
poly(aniline), have poor biocompatibility, biodegradability and are
Figure 2. Biomaterials-based approaches to spinal cord injury (SCI) therapeutic management. siRNA, small interference RNA; AONs, antisense oligonucleotides.
Table 1. Materials studied for nerve regeneration and tested in SCI models
Polymer Nature Type of bridge Combination therapy Ref.
PLA Synthetic, degradable Single walled conduit, electrospun
fibres
Drug release [109–111]
PLGA Synthetic, degradable Multiple channel; electrospun
fibres
Plasmid DNA; Schwann cells; self-
assembling peptides for growth
factor delivery; drug delivery
[112–116]
PCL Synthetic, degradable Porous scaffold Neural stem cells [117, 118]
PCLEEP Synthetic; degradable Electrospun fibres Drug delivery, siRNA [94, 119, 120]
P(HEMA) and copolymers Synthetic; non-degradable Hydrogel; scaffold Drug delivery; modified with
SIKVAV
[121–124]
Chitosan Natural; degradable Porous scaffold, conduit Endothelial cells; collagen hydrogel
as filler; bone marrow stem cells
[98, 99, 125–127]
Collagen Natural, degradable Electrospun fibres; oriented pore
channels; hydrogel
Growth factors; chondroitinase
ABC, stem cells
[100, 125, 128–130]
Gelatin Natural; degradable Scaffold Neuronalþ endothelial cell lines [131, 132]
Agarose Natural Hydrogel/scaffold Growth factors [20, 133]
Hyaluronic acid Natural Porous scaffold, scaffold coating,
hydrogel
Growth factors, cells [134–137]
PLA, poly(lactide); PLGA, poly(lactide-co-glycolide); PCL, poly(e-caprolactone); PCLEEP, poly(e-caprolactone-co-ethyl ethylene phosphate); P(HEMA),
poly(2-hydroxyehtyl methacrylate); siRNA, small interference RNA.
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difficult to process in different scaffold designs. In view of the above,
these polymers have been applied as coating or blends with other
synthetic [140, 141] or natural [142] polymers as a mean to improve
the construct biocompatibility while maintaining the electrical con-
ductance and, ultimately allowing the stimulation of neurite
outgrowth.
Scaffold design—architecture and topography
It is well accepted that axonal growth is useless if axons wander ran-
domly and that axons need guidance for functional regeneration to
occur [143]. However, the use of hollow conduits to bridge the le-
sion area in the spinal cord showed limited success [98, 109, 125].
Oudega et al. [109] implanted a PLA single walled conduit in a com-
plete transection SCI model and showed that the tube collapsed
soon after implantation, compromising axonal regeneration.
Conduits made of chitosan [125] or chitosan modified by plasma
treatment with laminin [98] were implanted in the spinal cord in a
4 mm gap resection model, but no improvement on axonal re-
growth or function was detected comparing to injured rats that did
not received a conduit. Furthermore, there is mounting evidence
that axons orient their processes according to the substrate and are
sensible to patterns on the surface the processes contact with [144–
147], suggesting that to integrate these features in the design of
nerve conduits can improve the guidance performance of these de-
vices. In view of the above, the development of an internal lumen
for such conduits is being investigated, namely the incorporation of
smaller channels, nanofibres or hydrogels. These can favour cell at-
tachment due to a higher surface area and can also serve for the in-
corporation of other molecular cues, like extracellular matrix
components and growth factors [148].
A very elegant work has been conducted by Shea and collabora-
tors using multiple channel poly(lactide-co-glycolide) (PLGA)
bridges in the spinal cord. The scaffolds containing channels be-
tween 150-250lm were prepared by gas foaming and particulate
leaching and showed to maintain their integrity 13 days after subcu-
taneous implantation [149]. When implanted in the spinal cord, lim-
ited macrophage infiltration was observed and the conduits were
stable at least for 6 weeks [112]. Complete degradation of the scaf-
folds was observed 6 months after implantation in the spinal cord
[150]. Furthermore, they demonstrated that the preparation of these
conduits is compatible with the delivery of bioactive growth factors
[149, 151, 152], DNA [113, 151] or lentivirus encoding for growth
factors [153, 154], showing significant improvements in regenera-
tion in SCI models.
More complex internal lumen architectures can be achieved us-
ing computer aided mould design and solid freeform fabrication
[155]. Using this approach, seven channel conduits were prepared
by injection moulding of a number of synthetic polymers. After im-
plantation in a complete transection model for SCI combined with
Schwann cells, conduits of an oligo(polyethylene glycol) fumarate,
positively charged, hydrogel showed better results in terms of num-
ber of axons colonizing the scaffold comparing to PLGA scaffolds
[114, 155]. Nevertheless, none of the materials tested achieved a
functional improvement 4 weeks post-implantation in a SCI model
[114].
Although still to be tested in vivo, collagen multichannel con-
duits based on electrospun fibres are being investigated and have
shown great potential as nerve guides due to the very high surface
area of the structure, mimicking the fascicles in nerve [156]. The
preparation of scaffolds with oriented microchannels has also been
explored using freeze-drying technique for polymers like collagen
[129] or gelatin [131] and blends with chitosan [157].
Alternatively to channels, hollow conduits have been filled with
hydrogels [100, 158]. In the context of SCI, a large-scale study was
performed using a chitosan conduit filled with a semi-fluid collagen
reports a significant improvement on the number of axons that can
cross the bridge in rats where collagen was used to fill the chitosan
tube, leading also to a significant increment in the Basso, Beattie and
Bresnahan locomotor rating scale [125].
Electrospun scaffolds have been widely investigated for periph-
eral nerve regeneration [87, 89, 94, 101, 119, 159–161], and more
recently, also explored in the context of SCI [100, 110, 115, 116,
162–165]. The first report testing electrospun fibres in a SCI sce-
nario was published in 2007. Meiners et al. [162] implanted a fabric
based on randomly oriented polyamide fibres in a hemisection SCI
model. The results were unsatisfactory, since the fabric tended to
fold, impairing axonal outgrowth. This study highlighted the impor-
tance of developing oriented nanofibrillar scaffolds for directing ax-
onal growth. Indeed, it has been shown that neurite extension is
increased when cells are cultured on aligned fibres, comparing to
random substrates [161, 166]. Hurtado et al. tested PLA conduits
consisting of a rolled mats of random or aligned micrometer fibres
implanted after complete transection of the spinal cord. Although
the functional recovery was not assessed in the study, the authors
showed a robust axonal regeneration in conduits with aligned fibres,
4 weeks after implantation [110]. Conversely, a preliminary in vivo
study using collagen nanofibrous scaffolds showed limited success
after 4 weeks of implantation [100]. The limited results are believed
to be related to the degradation of the conduit and the size of the fi-
bres. Fibres with a mean diameter around 200 nm [100] seem to be
less effective guiding axonal growth than micrometer fibres used in
other studies [110], although the role of fibre diameter on axonal
growth after SCI needs to be investigated in more detail [100].
An alternative scaffold design using electrospun fibres was pro-
posed by Gelain et al. [115]. The authors implanted 4 weeks after
the infliction of a contusive lesion layers of electrospun tubes with
210lm diameter filled with self-assembling peptides and fixed by a
PLGA / PCL electrospun sealing lamina. To implant the scaffold, the
scar tissue and debris were removed and then the cavity was filled.
The results showed significant axonal growth inside and between
the channels spanning the lesion. Functional motor recovery was
also observed, being statistical significance achieved only 22 weeks
after scaffold implantation [115].
The evidence shows that not only conduits and oriented channels
can guide axonal growth; topographic cues also play a major role
driving cell growth and conditioning their behaviour. Research on
the effect of topographic cues, and in particular of aligned sub-
strates, have been primarily focused on neurons. Aligned fibres and
micropatterned surfaces showed to promote directional axonal
growth [90, 91, 100, 167]. Moreover, it has been demonstrated that
aligned substrates affect adult stem cell differentiation, potentiating
differentiation into the neuronal lineage [168]. However, for func-
tional regeneration to occur, not only neuronal oriented growth is
required. The lack of organization of glial cells after injury is also as-
sociated to regeneration failure. In fact, regeneration through an
aligned fibrous scaffold was found to be supported by astrocyte mi-
gration along the fibre direction [110]. Indeed, astrocytes orient
their filamentous structure according to the topography of the sur-
face [107, 163, 169, 170]. Moreover, it has been reported that the
contact of astrocytes with fibres is able to promote a decrease on
glial fibrillary acidic protein expression [170] and an increase in
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glutamate uptake, what can contribute for neuroprotection in vivo
[107]. Furthermore, controlled micropatterned scaffolds showed to
influence astrocyte calcium signalling [171], being capable of revert-
ing mature astrocytes into radial glia-like cells, and consequently to
a more pro-regenerative phenotype [172]. Similarly, PLA aligned fi-
bres were found to favour cell de-differentiation towards radial glia
or neuronal progenitors. This positive effect was attributed to the
physical cues provided by the fibres, but also to the release of lactate
due to fibre biodegradation [173]. Published research shows that
cells from the immune system can also respond to topographic cues
and this may have a critical impact on the regeneration process. It
has been obeserved that macrophages cultured on electrospun fibres
of PLA [174] or PCL [175] secrete less pro-inflammatory cytokines
comparing to cells cultured on flat solvent-cast films, suggesting im-
proved biocompatibility of these surfaces [174]. McWhorter
et al.[176] proposed the use of surface topography to modulate mac-
rophage phenotype by controlling cell shape. To translate this
knowledge into nerve conduits can be a relevant approach towards
spinal cord regeneration taking in consideration macrophage role on
secondary injury after SCI [26]. Although microglia is responsible
for the early pro-inflammatory environment after SCI [177], little is
known about the response of these cells to surface topography. The
effect of nanostructured silicone on BV-2 (a microglia cell line) cell
adhesion was investigated, showing that cells can undergo marked
morphogenic changes, according to feature size (30 nm–2mm)
[178]. Microglia can also interact mechanically with nanostructured
3D features, like micro-pillars (4.7mm of height), adapting actin cy-
toskeleton to these structures [179]. This microglia morphologic
plasticity was also described by us for primary cultures seeded on
P(TMC-CL) substrates. On fibrous surfaces microglia showed small
cytoplasm and more ramified structure, comparing to flat solvent-
cast films [180]. However, in our study we did not observe a correla-
tion between the morphologic alterations and the cytokine release
profile, in opposition to previous reports by others using macro-
phages [174, 175]. Still, the topography of the surface showed to in-
fluence microglia ability to form multinuclear giant cells, when cells
are challenged with myelin in the culture media [180]. These results
highlighted the need to understand the functional relevance of the
reported alterations in cell morphology. Furthermore, no extrapola-
tions from the macrophage behaviour can be done, as microglia re-
act differently to stimuli, despite sharing relevant lineage features
with macrophages [181–183].
Drug releasing scaffolds
The localized delivery of the drugs/therapeutics described in the first
part of this review to the spinal cord injured area has been explored
as a mean to reduce side effects associated with systemic administra-
tion as well as a way to improve drug efficiency [20].
Drug delivery into the intrathecal space after lesion in the spinal
cord have been explored using injectable hydrogels as carriers.
Hydrogels based on hyaluronan and methyl cellulose were proposed
for the delivery of neurotrophic factors [123, 136]. Similarly, injec-
tion of fibrin loaded with NT-3 showed to promote functional im-
provements after SCI, comparing to unloaded hydrogels [184].
Chondroitinase ABC has also been delivered through fibrin hydro-
gels to an injured spinal cord [185].
Alternatively, different drugs have been loaded in scaffolds to be
implanted in the lesion and release therapeutic molecules in situ.
Research on PLGA multiple lumen conduits showed that these scaf-
folds are compatible with the delivery of NGF [149], vascular
endothelial growth factor or fibroblast growth factor [152], showing
positive results when implanted in SCI model.
A number of researchers have focused on combining drugs with
electrospun scaffolds. Electrospun fibres have been loaded with
growth factors [94, 128] or cAMP [186], aiming to promote neuro-
protection. An alternative approach was explored by combining 6-
aminonicotinamide in PLA fibres as a mean to limit astrocyte prolif-
eration [111], or loading ibuprofen in P(TMC-CL) electrospun fi-
bres in order to reduce local inflammatory response [187]. Collagen
fibres were also prepared for the delivery of NT-3 and chondroiti-
nase ABC [128]. An option for nanofibrous scaffolds is to be applied
as patches for drug delivery in the spinal cord. Fibrous patches
loaded with rolipram, a small molecule that can enhance cAMP ac-
tivity in neurons, and suppress inflammatory response, favouring
nerve regeneration [188], showed to improve locomotor function in
rats with SCI in comparison to unloaded patches from the third
week on after implantation [116]. To better control the release of
the drug and increase drug loading, the electrospun fibres were com-
bined with an alginate hydrogel. However, the use of high drug
doses showed to lead to toxic effects and an increased mortality rate
[165].
Drug loading in nanoparticles subsequently delivered to the spi-
nal cord within a scaffold has been investigated for drugs, such as
MP or minocycline. An agarose hydrogel containing PLGA nanopar-
ticles loaded with MP was implanted in a contusion model of SCI
leading to reduced lesion volume and macrophage infiltration [20].
For the delivery of minocycline, drug loaded nanoparticles based on
PCL and polyethylene glycol (PEG) were applied, being able to re-
duce activation and proliferation of microglia/macrophages in vivo
[189].
Scaffolds containing genetic material can serve as depots for the
in situ delivery of genes to cells at a lesion, potentially inducing the
expression of a therapeutic protein for longer periods and higher
concentrations, as compared with direct protein delivery [190]. In
the context of nerve regeneration, PLGA disks loaded with poly(eth-
ylene imine)-DNA nanoparticles containing a plasmid encoding for
NGF showed to promote axonal elongation in dorsal root ganglia
neurons co-cultured with human embryonic kidney 293T cells
[191]. Particularly in a SCI scenario, lipid-DNA particles were incor-
porated in a PLGA channel bridge and a high expression of the re-
porter gene was detected in the spinal cord during 3 weeks [88].
However, to achieve functional improvements the implantation of
conduits containing more efficient gene delivery vectors, namely vi-
ral vectors (lentivirus), was needed [153, 154]. A very promising al-
ternative currently under investigation is to load scaffold with
nanoparticles carrying small interference RNA (siRNA) [192, 193]
or microRNAs [194] targeting inhibitory pathways of the regenera-
tive process.
Cellular bridges
Research in biomaterials to assist the delivery of cells to the CNS,
and to the spinal cord has been primarily devoted to the use of hy-
drogels [82, 83, 195, 196]. Hydrogels appeared to address the need
to improve cell survival and/or to modulate cell differentiation after
implantation [197]. However, recent reports in the open literature
demonstrate that the implantation of scaffolds colonized with cells
represents a promising complement for design of effective cellular
therapies. This strategy is the focus of this section.
Xue et al. [198] investigated the implantation of a chitin tube
loaded with mesenchymal stem cells (MSC) immediately after spinal
cord hemisection. The authors showed that the implantation of the
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scaffold was able to reduce scar formation, establishing a favourable
environment for cell survival and proliferation. In a more complex
approach, Zeng et al. [132] applied gelatin porous sponges popu-
lated with MSC manipulated in vitro. First, the cells were genetically
engineered in order to induce overexpression of a NT-3 receptor,
the tyrosine kinase C. Subsequently, the MSC were co-cultured with
Schwann cells overexpressing NT-3. The authors demonstrated that
this process favours MSC differentiation towards the neuronal line-
age. The implantation of the scaffolds colonized with the engineered
MSC after complete transection of the spinal cord showed to im-
prove functional recovery comparing to plain sponges and to sup-
port integration in the host neural network [132].
A popular cell type applied in cellular therapies for SCI are neu-
ral stem cells (NSC), which can be obtained from different sources.
NSCs are committed to the neural lineage and are believed to con-
tribute to neuronal regeneration by favouring host axonal regenera-
tion due to trophic effect and by replacing damaged/lost cells. PLGA
multichannel conduits [199] and chitosan tubes [127] were im-
planted in the spinal cord combined with NSC, with some degree of
success. Improvements on transplanted cell survival were reported,
but no significant functional recovery was reported. A recent study
describes the use of NSC obtained from induced embryonic fibro-
blasts seeded on gelatin-electrospun PLGA/PEG scaffolds. The scaf-
folds were prepared by assembling a gelatin sponge and a PLGA/
PEG electrospun mesh and rolling it together into a cylinder. Eight
weeks after implantation in a complete transected spinal cord, the
scaffolds showed to reduce cavity formation, supporting NSC sur-
vival and proliferation. The authors suggested that cell survival con-
tributed to functional recovery, however the study did not disclose
the effect of the scaffold on itself, as scaffolds without cells were not
tested [200]. Collagen porous sponges showed also to support NSC
delivery and survival, being able to reduce the formation of a fluid-
filled cyst comparing to non-treated animals when implanted in a
5 mm full resection gap model of SCI [130].
A different approach was explored by Jian et al. [201] that used
a glioma cell line as extracellular matrix depositors to coat a chito-
san tubular scaffold prior implantation. Interestingly, such enriched
scaffolds showed to favour stem cell differentiation into the neuro-
nal lineage in vitro. However, in vivo, modest improvements in
function were found only if scaffolds were combined with a glyco-
gen synthetase inhibitor, known to play a role on stem cell differen-
tiation [201].
Future perspectives
Much research in the field of SCI aims at the understanding of the
fundamental cellular and molecular mechanisms that underlie this
multi-factorial clinical condition. Immense progress has been made
in the last decades and at present the field believes that regeneration
can occur, at least to a certain extent, if the environment at the le-
sion site is tuned to a pro-regenerative context. Still, the major chal-
lenge is to develop effective therapies based on the advances
achieved on basic research. As in other field of tissue engineering
and regenerative medicine, biomaterials and scaffold structures are
expected to play a key role on the design of such advanced
therapies.
Nerve conduits have been investigated for long in the field of
SCI, although their use in the clinical setting was never achieved.
The design of these scaffolds has been increasing in complexity, as it
is happening with the proposed therapeutic approaches. The devel-
opment of combinatorial strategies deals with the difficult task of
identifying the appropriate scaffold design, the best cell source and
the correct drug/molecule cocktail and dose. This will be needed to
respond to the multi-factorial inhibitory environment formed in the
aftermath of a SCI. But important progress was attained recently,
with the start of a clinical trial to assess the safety of the implanta-
tion of a PLGA/poly(lysine) scaffold in SCI patients [40].
Additionally, a more ambitious trial was recently launched in China,
proposing to evaluate functional improvements after implantation of
a collagen scaffold loaded with MSCs and growth factors [40]. To
perform clinical trials with implantable scaffolds represents a major
achievement that will certainly push forward the biomaterials and tis-
sue engineering research in SCI. The expected data will be paramount
for the establishment of such ‘bridges’ as powerful tools in the design
of much awaited effective therapeutical strategies.
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